Refine
Has Fulltext
- yes (71)
Is part of the Bibliography
- yes (71)
Year of publication
Document Type
- Journal article (71) (remove)
Language
- English (71) (remove)
Keywords
- breast cancer (17)
- ovarian cancer (7)
- 3D printing (4)
- expression (4)
- gynecology (4)
- education (3)
- inflammation (3)
- ketogenic diet (3)
- survival (3)
- teaching (3)
- Akt (2)
- BRENDA (2)
- CD39 (2)
- CD73 (2)
- Ketogenic diet (2)
- Metastatic breast cancer (2)
- NSG (2)
- T cells (2)
- VEGF (2)
- adenosine (2)
- apoptosis (2)
- autophagy (2)
- blood-brain barrier (2)
- cancer (2)
- cancer detection and diagnosis (2)
- cytokines (2)
- disease (2)
- gene (2)
- humanized mice (2)
- immune escape (2)
- lymph nodes (2)
- pelvic examination (2)
- pelvic palpation (2)
- pregnancy (2)
- stress (2)
- trastuzumab (2)
- tumor stem cells (2)
- visualization (2)
- 2-APB (1)
- 3D tissue model (1)
- ADCC (1)
- Astrocytic tumor (1)
- Axonal degeneration (1)
- B7-H1 (1)
- Blood–brain barrier (1)
- Blut (1)
- CD74 (1)
- COVID-19 (1)
- CX3CL1 (1)
- CXCL13 (1)
- Ca2+ release activated Ca2+ channel (1)
- Chirurgie (1)
- Coronavirus Disease 2019 (1)
- Covid-19 (1)
- DNA repair protraction (1)
- Diabetic polyneuropathy (1)
- Epidural Analgesia (1)
- Expression (1)
- FDM (1)
- FWGE (1)
- Fettgehalt (1)
- Genetic causes of cancer (1)
- Glioblastoma cell line (1)
- Glioblastoma multiforme (1)
- HER2 (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- HERV-K (1)
- HLA class II (1)
- HLA peptidome (1)
- Health care service research (1)
- Healthcare Cost (1)
- Healthcare Economics (1)
- High fat diet (1)
- Human endogenous retrovirus (1)
- In vitro models (1)
- Ketogene Kost (1)
- Krebs <Medizin> (1)
- Krebskranker (1)
- L. reuteri (1)
- LPS (1)
- Labour Analgesia (1)
- Labour Pain (1)
- Large loop excision of the transformation zone (LLETZ) (1)
- Lebensqualität (1)
- Loop electrosurgical excision procedure (LEEP) (1)
- MMP (1)
- MRSA (1)
- MRSA - methicillin-resistant Staphylococcus aureus (1)
- Matrix metalloproteinases (1)
- Medicine (1)
- Medizin (1)
- Molecular biology (1)
- Motor nerve biopsy (1)
- NRG1 (1)
- NSG-SGM3 (1)
- NVP-BEZ235 (1)
- Nectin‐2 (1)
- Neuropathy (1)
- Neurotrophic factors (1)
- Non-coding RNAs (1)
- Novel PI3K (1)
- PC-1 blockade (1)
- PCR analysis (1)
- PD-1 (1)
- PD-L1 (1)
- Parkinson’s disease (1)
- Patient Controlled Analgesia (1)
- Patient Satisfaction (1)
- Patient-centered registry (1)
- Patient’s needs (1)
- Pelvisio® (1)
- RT-qPCT (1)
- Remifentanil (1)
- SH-6 (1)
- SLA (1)
- SOCE (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Staphylococcus aureus (1)
- Staphylococcus aureus immune response (1)
- T-DM1 (1)
- TGF-beta (1)
- TKTL1 (1)
- Toll-like receptor signaling (1)
- UME6 (1)
- VE-cadherin (1)
- accessibility (1)
- acute respiratory distress syndrome (1)
- advanced breast cancer (1)
- age factors (1)
- aged (1)
- aged 80 and over (1)
- animal models (1)
- anti-hormonal therapy (1)
- anti-tumor effects (1)
- argeted therapy (1)
- ascites (1)
- astrocytic tumor (1)
- astrocytoma (1)
- axillary dissection (1)
- bacteria (1)
- bacterial infection model (1)
- benzoquinone (1)
- bioimpedance analysis (1)
- bioinformatics (1)
- biomarker (1)
- bioreactor culture (1)
- blood lipids; fat loss; running performance (1)
- blood-brain barrier (BBB) model (1)
- bone metastases (1)
- brain metastases (1)
- brain metastasis (1)
- brain-metastasis (1)
- breast cancer imaging (1)
- breast cancer metastases (1)
- breast cancer subtypes (1)
- cachexia (1)
- calprotectin (1)
- cancer cell lines (1)
- cancer cells (1)
- cancer chemotherapy (1)
- cancer dissemination (1)
- cancer microenvironment (1)
- cancer patients (1)
- cancer risk factors (1)
- cancer stem cell immunology (1)
- cancer stem cells (1)
- cancer treatment (1)
- cell lung cancer (1)
- cervical dysplasia (1)
- chemotherapy (1)
- chronic periodontitis (1)
- claudin 5 (1)
- co-culture (1)
- combinatorial drug predictions (1)
- common variable immunodeficiency (CVID) (1)
- conventional imaging (1)
- cord blood (1)
- cross-sectional imaging (1)
- cytostatic (1)
- cytotoxicity (1)
- delay of therapy (1)
- diseases of the nervous system (1)
- dysplasia (1)
- endocrine therapy (1)
- epidemiology (1)
- evidence‐based medicine (1)
- exercise (1)
- exosomes (1)
- expression pattern (1)
- feasibility (1)
- fecal short-chain fatty acids (1)
- female (1)
- fiber intake (1)
- follow up (1)
- fused deposition modeling (FDM) (1)
- gene expression (1)
- genetic testing (1)
- genital warts (1)
- geographic information science (1)
- glioblastoma (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (1)
- glioblastoma stem cell (1)
- glioma (1)
- gliomas (1)
- glucose (1)
- growth (1)
- growth differentiation factor 15 (1)
- guideline adherent treatment (1)
- gynecologic surgical procedures/methods (1)
- health care providers (1)
- health care service research (1)
- histology (1)
- histopathology (1)
- hormona therapy (1)
- hormones (1)
- human genetics (1)
- human induced pluripotent stem cells (hiPSCs)human induced pluripotent stem cells (hiPSCs) (1)
- human papillomavirus (1)
- humanized hemato-lymphoid mice (1)
- hyaluronan-related enzymes (1)
- hypoxia (1)
- immune response (1)
- immunohistochemistry (1)
- immunoresistance (1)
- immunosurveillance (1)
- immunotherapies (1)
- immunotherapy (1)
- implementation (1)
- inborn errors of immunity (IEIs) (1)
- individual mind state (1)
- inflammatory cascades (1)
- insulin (1)
- insulin-like growth factor 1 (IGF1) (1)
- intestinal inflammation (1)
- intestinal permeability (1)
- invasiveness (1)
- ionizing radiation (1)
- ketogenic dients (1)
- ketone bodies (1)
- laparoscopy/methods (1)
- large loop excision of the transformation zone (LLETZ) (1)
- latency (1)
- lifestyle habits (1)
- low carb diet (1)
- low carbohydrate diet (1)
- lung-cancer (1)
- m-Health (1)
- mTOR Inhibitor (1)
- mammography (1)
- matrix metalloproteinase (1)
- medicine (1)
- melanoma (1)
- metabolic profile (1)
- metabolism (1)
- metastasis (1)
- miRNA (1)
- miRNAs (1)
- mice (1)
- microRNA (1)
- microarray (1)
- microbiota (1)
- microglia (1)
- microna profiles (1)
- middle Aged (1)
- modular tumor tissue models (1)
- monocyte (1)
- monocyte subsets (1)
- monocytes (1)
- morphogenesis (1)
- motivational level (1)
- mouse brain (1)
- multiple sclerosis (1)
- multipotent fetal neural stem cells (fNSCs) (1)
- neoadjuvant therapies (1)
- neonatal immunology (1)
- neural stem cell (1)
- neurodegeneration (1)
- neurogenesis (1)
- neuroimmunology (1)
- neuroinflammation (1)
- neurological disorders (1)
- neurovascular unit in vitro (1)
- number of (1)
- p53 (1)
- pathways (1)
- patient safety (1)
- patient serum (1)
- pelvic organ prolapse/surgery (1)
- peripheral blood (1)
- peritoneal metastasis (1)
- pertuzumab (1)
- pilot study (1)
- plaque (1)
- polyvinylidene fluoride (PVDF) (1)
- positive nodal status (1)
- post-neoadjuvant therapies (1)
- postoperative complications/epidemiology (1)
- postpartum (1)
- prediction (1)
- pregnancy gingivitis (1)
- premalignant lesion (1)
- preterm infants (1)
- primary immunodeficiency (1)
- probiotic lozenges (1)
- prognosis (1)
- prognostic marker (1)
- psychological distress (1)
- quality of care (1)
- quality of life (1)
- radiosensibility (1)
- reactive oxygen species (1)
- reconstructive surgical procedures/methods (1)
- regulator (1)
- rehabilitation (1)
- retrospective Studies (1)
- review (1)
- rheumatoid arthritis (1)
- risk (1)
- robotic complications (1)
- robotic hysterectomy (1)
- robotic sacrocolpopexy (1)
- safety (1)
- score (1)
- seahorse (1)
- sentinel (1)
- serum (1)
- signature (1)
- simulation (1)
- skeleton (1)
- staib agar (1)
- staphylocccal infection/epidemiology (1)
- staphylococcal abscess (1)
- stromal hyaluronan (1)
- subgingival (1)
- subventricular zone (1)
- supportive care (1)
- surgical Mesh (1)
- survivors (1)
- symptom burden (1)
- transforming growth factor-beta-1 (1)
- trastuzumab deruxtecan (1)
- tumor associated macrophages (1)
- tumor dormancy (1)
- tumor immune escape (1)
- tumor immunology (1)
- tumor immunosurveillance (1)
- tumor infiltrating lymphocytes (1)
- tumor size (1)
- tumor-associated hyaluronan staining pattern (1)
- tumor-infiltrating lymphocytes (1)
- tumor-propagating cells (1)
- tumors (1)
- tumour immunology (1)
- ultrasound (1)
- unmet needs (1)
- urinary incontinence/surgery (1)
- uterine prolapse/surgery (1)
- vagina/surgery (1)
- vascular permeability (1)
- viral load (1)
- virtual (1)
- virulence (1)
- zonulin (1)
- β-Hydroxybutyrate (1)
Institute
- Frauenklinik und Poliklinik (71) (remove)
EU-Project number / Contract (GA) number
- 259867 (1)
A 3D printed model of the female pelvis for practical education of gynecological pelvic examination
(2022)
Background
Pelvic palpation is a core component of every Gynecologic examination. It requires vigorous training, which is difficult due to its intimate nature, leading to a need of simulation. Up until now, there are mainly models available for mere palpation which do not offer adequate visualization of the concerning anatomical structures. In this study we present a 3D printed model of the female pelvis. It can improve both the practical teaching of gynecological pelvic examination for health care professionals and the spatial understanding of the relevant anatomy.
Methods
We developed a virtual, simplified model showing selected parts of the female pelvis. 3D printing was used to create a physical model.
Results
The life-size 3D printed model has the ability of being physically assembled step by step by its users. Consequently, it improves teaching especially when combining it with commercial phantoms, which are built solely for palpation training. This is achieved by correlating haptic and visual sensations with the resulting feedback received.
Conclusion
The presented 3D printed model of the female pelvis can be of aid for visualizing and teaching pelvic anatomy and examination to medical staff. 3D printing provides the possibility of creating, multiplying, adapting and sharing such data worldwide with little investment of resources. Thus, an important contribution to the international medical community can be made for training this challenging examination.
Glioblastomas are characterized by an aggressive local growth pattern, a marked degree of invasiveness and poor prognosis. Tumor invasiveness is facilitated by the increased activity of proteolytic enzymes which are involved in destruction of the extracellular matrix of the surrounding healthy brain tissue. Elevated levels of matrix metalloproteinases (MMPs) were found in glioblastoma (GBM) cell-lines, as well as in GBM biopsies as compared with low-grade astrocytoma (LGA) and normal brain samples, indicating a role in malignant progression. A careful review of the available literature revealed that both the expression and role of several of the 23 human MMP proteins is controversely discussed and for some there are no data available at all. We therefore screened a panel of 15 LGA and 15 GBM biopsy samples for those MMPs for which there is either no, very limited or even contradictory data available. Hence, this is the first complete compilation of the expression pattern of all 23 human MMPs in astrocytic tumors. This study will support a better understanding of the specific expression patterns and interaction of proteolytic enzymes in malignant human glioma and may provide additional starting points for targeted patient therapy.
Background: Ketogenic diets (KDs) have gained some popularity not only as effective weight-loss diets and treatment options for several diseases, but also among healthy and physically active individuals for various reasons. However, data on the effects of ketosis in the latter group of individuals are scarce. We therefore collected pilot data on the physiological response to a self-prescribed ketogenic diet lasting 5-7 weeks in a small cohort of healthy and physically active individuals. Methods: Twelve subjects (7 males, 5 females, age 24-60 years) who followed moderate to intensive exercise routines underwent blood testing, bioelectrical impedance analysis (BIA) and spiroergometry during an incremental treadmill test. On the next day, they went on a self-prescribed KD for a median of 38 days (range 35-50 days), after which the same tests were performed again. Ketosis was self-monitored by urinary ketone strips. Subjective feeling during the diet was assessed by a questionnaire after the intervention. Due to the small and heterogenous sample, the results are interpreted in the context of the already existing literature. Results: The KDs were tolerated well by the majority of individuals. Impaired recovery from exercise remained the most frequently reported side effect until the end of the study. Most blood parameters remained stable during the intervention. However, there were significant elevations of total and LDL cholesterol concentrations (p<0.01) and a trend towards increased HDL-cholesterol (p=0.05). The drastic reduction of carbohydrates had no statistically significant influence on running performance judged by the time to exhaustion, VO2max and respiratory compensation points. BIA measurements showed significant increases in phase angle (p=0.01) indicating improvements of body composition with an estimated decrease of 3.4 kg of fat mass (p=0.002) and gain of 1.3 kg of fat free mass. We discuss the validity of these estimates taking into account a possibly altered hydration status due to the KD. Conclusions: Active healthy individuals will probably experience no major problems during a short term KD lasting several weeks. The drastically reduced carbohydrate content of the diet seems to be no limiting factor for running performance. In addition, improvements in body composition can be expected. While most biochemical parameters are not influenced by the diet, there seems to be an impact on the blood lipid profile that could be considered problematic with respect to cardiovascular disease risk. However, the predictive role of cholesterol levels alone in individuals undergoing regular physical activity remains to be elucidated.
Background
Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known about the effect of adenosine on myeloid cells. Considering that tumor associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) constitute up to 20 % of OvCA tissue, we investigated the effect of adenosine on myeloid cells and explored a possible contribution of myeloid cells to adenosine generation in vitro and ex vivo.
Methods
Monocytes were used as human blood-derived myeloid cells. After co-incubation with SK-OV-3 or OAW-42 OvCA cells, monocyte migration was determined in transwell assays. For conversion into M2-polarized “TAM-like” macrophages, monocytes were co-incubated with OAW-42 cells. Ex vivo TAMs were obtained from OvCA ascites. Macrophage phenotypes were investigated by intracellular staining for IL-10 and IL-12. CD39 and CD73 expression were assessed by FACS analysis both on in vitro-induced TAM-like macrophages and on ascites-derived ex situ-TAMs. Myeloid cells in solid tumor tissue were analyzed by immunohistochemistry. Generation of biologically active adenosine by TAM-like macrophages was measured in luciferase-based reporter assays. Functional effects of adenosine were investigated in proliferation-experiments with CD4+ T cells and specific inhibitors.
Results
When CD39 or CD73 activity on OvCA cells were blocked, the migration of monocytes towards OvCA cells was significantly decreased. In vivo, myeloid cells in solid ovarian cancer tissue were found to express CD39 whereas CD73 was mainly detected on stromal fibroblasts. Ex situ-TAMs and in vitro differentiated TAM-like cells, however, upregulated the expression of CD39 and CD73 compared to monocytes or M1 macrophages. Expression of ectonucleotidases also translated into increased levels of biologically active adenosine. Accordingly, co-incubation with these TAMs suppressed CD4+ T cell proliferation which could be rescued via blockade of CD39 or CD73.
Conclusion
Adenosine generated by OvCA cells likely contributes to the recruitment of TAMs which further amplify adenosine-dependent immunosuppression via additional ectonucleotidase activity. In solid ovarian cancer tissue, TAMs express CD39 while CD73 is found on stromal fibroblasts. Accordingly, small molecule inhibitors of CD39 or CD73 could improve immune responses in ovarian cancer.
Brain metastases are the most severe tumorous spread during breast cancer disease. They are associated with a limited quality of life and a very poor overall survival. A subtype of extracellular vesicles, exosomes, are sequestered by all kinds of cells, including tumor cells, and play a role in cell-cell communication. Exosomes contain, among others, microRNAs (miRs). Exosomes can be taken up by other cells in the body, and their active molecules can affect the cellular process in target cells. Tumor-secreted exosomes can affect the integrity of the blood-brain barrier (BBB) and have an impact on brain metastases forming. Serum samples from healthy donors, breast cancer patients with primary tumors, or with brain, bone, or visceral metastases were used to isolate exosomes and exosomal miRs. Exosomes expressed exosomal markers CD63 and CD9, and their amount did not vary significantly between groups, as shown by Western blot and ELISA. The selected 48 miRs were detected using real-time PCR. Area under the receiver-operating characteristic curve (AUC) was used to evaluate the diagnostic accuracy. We identified two miRs with the potential to serve as prognostic markers for brain metastases. Hsa-miR-576-3p was significantly upregulated, and hsa-miR-130a-3p was significantly downregulated in exosomes from breast cancer patients with cerebral metastases with AUC: 0.705 and 0.699, respectively. Furthermore, correlation of miR levels with tumor markers revealed that hsa-miR-340-5p levels were significantly correlated with the percentage of Ki67-positive tumor cells, while hsa-miR-342-3p levels were inversely correlated with tumor staging. Analysis of the expression levels of miRs in serum exosomes from breast cancer patients has the potential to identify new, non-invasive, blood-borne prognostic molecular markers to predict the potential for brain metastasis in breast cancer. Additional functional analyzes and careful validation of the identified markers are required before their potential future diagnostic use.
The ectonucleotidases CD39 and CD73 degrade ATP to adenosine which inhibits immune responses via the \(A_{2A}\) adenosine receptor (ADORA2A) on T and NK cells. The current study investigates the potential therapeutic use of the specific anti CD39- and anti CD73-antibodies A1 (CD39) and 7G2 (CD73) as these two ectonucleotidases are overexpressed in ovarian cancer (OvCA). As expected, NK cell cytotoxicity against the human ovarian cancer cell lines OAW-42 or SK-OV-3 was significantly increased in the presence of A1 or 7G2 antibody. While this might partly be due to antibody-dependent cell-mediated cytotoxicity, a luciferase-dependent assay for quantifying biologically active adenosine further showed that A1 and 7G2 can inhibit CD39 and CD73-dependent adenosine-generation. In turn, the reduction in adenosine levels achieved by addition of A1 and 7G2 to OAW-42 or SK-OV-3 cells was found to de-inhibit the proliferation of \(CD4^+\) T cells in coculture with OvCA cells. Likewise, blocking of CD39 and CD73 on OvCA cells via A1 and 7G2 led to an increased cytotoxicity of alloreactive primed T cells. Thus, antibodies like A1 and 7G2 could improve targeted therapy in ovarian cancer not only by specifically labeling overexpressed antigens but also by blocking adenosine-dependent immune evasion in this immunogenic malignancy.
Simple Summary
Anti-hormonal therapie regimes are well established in oncological treatments in breast cancer. In contrast there is limited knowledge of their effects on metastatic brain metastases in advanced breast cancer and their ability to cross the blood brain-barrier. In this review, we point out the usual antihormonal therapy options in the primary disease, but also in metastatic breast cancer. In addition, we explain the epidemiological facts of brain metastases, as well as the basics of the blood-brain barrier and how this is overcome by metastase. Last but not least, we deal with the known anti-hormonal therapy options and present clinical studies on their intracerebral effect, as well as the known basics of their blood-brain barrier penetration. Not all common anti-hormonal therapeutics are able to penetrate the CNS. It is therefore important for the treating oncologists to use substances that have been proven to cross the BBB, despite the limited data available. Aromataseinhibitors, especially letrozole, probably also tamoxifen, everolimus and CDK4/6 inhibitors, especially abemaciclib, appear to act intracerebrally by overcoming the blood-brain barrier. Nevertheless, further data must be obtained in basic research, but also health care research in relation to patients with brain metastases.
Abstract
The molecular receptor status of breast cancer has implications for prognosis and long-term metastasis. Although metastatic luminal B-like, hormone-receptor-positive, HER2−negative, breast cancer causes brain metastases less frequently than other subtypes, though tumor metastases in the brain are increasingly being detected of this patient group. Despite the many years of tried and tested use of a wide variety of anti-hormonal therapeutic agents, there is insufficient data on their intracerebral effectiveness and their ability to cross the blood-brain barrier. In this review, we therefore summarize the current state of knowledge on anti-hormonal therapy and its intracerebral impact and effects on the blood-brain barrier in breast cancer.
Background
Currently ketogenic diets (KDs) are hyped as an anti-tumor intervention aimed at exploiting the metabolic abnormalities of cancer cells. However, while data in humans is sparse, translation of murine tumor models to the clinic is further hampered by small sample sizes, heterogeneous settings and mixed results concerning tumor growth retardation. The aim was therefore to synthesize the evidence for a growth inhibiting effect of KDs when used as a monotherapy in mice.
Methods
We conducted a Bayesian random effects meta-analysis on all studies assessing the survival (defined as the time to reach a pre-defined endpoint such as tumor volume) of mice on an unrestricted KD compared to a high carbohydrate standard diet (SD). For 12 studies meeting the inclusion criteria either a mean survival time ratio (MR) or hazard ratio (HR) between the KD and SD groups could be obtained. The posterior estimates for the MR and HR averaged over four priors on the between-study heterogeneity τ\(^{2}\) were MR = 0.85 (95% highest posterior density interval (HPDI) = [0.73, 0.97]) and HR = 0.55 (95% HPDI = [0.26, 0.87]), indicating a significant overall benefit of the KD in terms of prolonged mean survival times and reduced hazard rate. All studies that used a brain tumor model also chose a late starting point for the KD (at least one day after tumor initiation) which accounted for 26% of the heterogeneity. In this subgroup the KD was less effective (MR = 0.89, 95% HPDI = [0.76, 1.04]).
Conclusions
There was an overall tumor growth delaying effect of unrestricted KDs in mice. Future experiments should aim at differentiating the effects of KD timing versus tumor location, since external evidence is currently consistent with an influence of both of these factors.
Background
Fermented wheat germ extract (FWGE) sold under the trade name Avemar exhibits anticancer activity in vitro and in vivo. Its mechanisms of action are divided into antiproliferative and antimetabolic effects. Its influcence on cancer cell metabolism needs further investigation. One objective of this study, therefore, was to further elucidate the antimetabolic action of FWGE. The anticancer compound 2,6-dimethoxy-1,4-benzoquinone (DMBQ) is the major bioactive compound in FWGE and is probably responsible for its anticancer activity. The second objective of this study was to compare the antiproliferative properties in vitro of FWGE and the DMBQ compound.
Methods
The IC\(_{50}\) values of FWGE were determined for nine human cancer cell lines after 24 h of culture. The DMBQ compound was used at a concentration of 24 μmol/l, which is equal to the molar concentration of DMBQ in FWGE. Cell viability, cell cycle, cellular redox state, glucose consumption, lactic acid production, cellular ATP levels, and the NADH/NAD\(^+\) ratio were measured.
Results
The mean IC\(_{50}\) value of FWGE for the nine human cancer cell lines tested was 10 mg/ml. Both FWGE (10 mg/ml) and the DMBQ compound (24 μmol/l) induced massive cell damage within 24 h after starting treatment, with changes in the cellular redox state secondary to formation of intracellular reactive oxygen species. Unlike the DMBQ compound, which was only cytotoxic, FWGE exhibited cytostatic and growth delay effects in addition to cytotoxicity. Both cytostatic and growth delay effects were linked to impaired glucose utilization which influenced the cell cycle, cellular ATP levels, and the NADH/NAD\(^+\) ratio. The growth delay effect in response to FWGE treatment led to induction of autophagy.
Conclusions
FWGE and the DMBQ compound both induced oxidative stress-promoted cytotoxicity. In addition, FWGE exhibited cytostatic and growth delay effects associated with impaired glucose utilization which led to autophagy, a possible previously unknown mechanism behind the influence of FWGE on cancer cell metabolism.
Increased intestinal permeability and inflammation, both fueled by dysbiosis, appear to contribute to rheumatoid arthritis (RA) pathogenesis. This single-center pilot study aimed to investigate zonulin, a marker of intestinal permeability, and calprotectin, a marker of intestinal inflammation, measured in serum and fecal samples of RA patients using commercially available kits. We also analyzed plasma lipopolysaccharide (LPS) levels, a marker of intestinal permeability and inflammation. Furthermore, univariate, and multivariate regression analyses were carried out to determine whether or not there were associations of zonulin and calprotectin with LPS, BMI, gender, age, RA-specific parameters, fiber intake, and short-chain fatty acids in the gut. Serum zonulin levels were more likely to be abnormal with a longer disease duration and fecal zonulin levels were inversely associated with age. A strong association between fecal and serum calprotectin and between fecal calprotectin and LPS were found in males, but not in females, independent of other biomarkers, suggesting that fecal calprotectin may be a more specific biomarker than serum calprotectin is of intestinal inflammation in RA. Since this was a proof-of-principle study without a healthy control group, further research is needed to validate fecal and serum zonulin as valid biomarkers of RA in comparison with other promising biomarkers.